Neil Clark, Chief Executive Officer of Destiny Pharma #DEST provides updates on the Phase 2b clinical study of their lead asset XF-73
Episode 7, Sep 17, 2020, 12:08 PM
Neil Clark, Chief Executive Officer of Destiny Pharma #DEST provides updates on the Phase 2b clinical study of their lead asset XF-73 in the prevention of post-surgical infections and other parts of the business.
Neil Clark, Chief Executive Officer of Destiny Pharma #DEST provides updates on the Phase 2b clinical study of their lead asset XF-73 in the prevention of post-surgical infections and other parts of the business.
Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections today announces an update on it its XF-73 Phase 2b clinical study with 88 patients out of the target of 125 now recruited. There is good momentum in patient recruitment which we expect to continue into the Autumn.
The Phase 2b clinical study is recruiting patients undergoing open heart surgery in United States and Europe. Barring any further impact from COVID-19 the study is on plan to complete recruitment by the end of 2020 and report results in Q1 2021.
Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections today announces an update on it its XF-73 Phase 2b clinical study with 88 patients out of the target of 125 now recruited. There is good momentum in patient recruitment which we expect to continue into the Autumn.
The Phase 2b clinical study is recruiting patients undergoing open heart surgery in United States and Europe. Barring any further impact from COVID-19 the study is on plan to complete recruitment by the end of 2020 and report results in Q1 2021.
Neil Clark, Chief Executive Officer of Destiny Pharma, said: "We are very pleased to report a significant increase in the screening and recruitment of patients in our lead clinical study testing XF-73 as a novel product preventing the incidence of post-surgical infections such as MRSA. In the past few months we have agreed a protocol amendment with the FDA and also reported excellent interim safety data and are looking forward to completing recruitment and reporting the results."
Vox Markets is revolutionising the way companies engage with shareholders and the stock market at large. By aggregating IR and digital content onto one secure and compliant platform, Vox Markets has established itself as the go-to resource for the investment community.
Vox Markets is revolutionising the way companies engage with shareholders and the stock market at large. By aggregating IR and digital content onto one secure and compliant platform, Vox Markets has established itself as the go-to resource for the investment community.
#VoxMarkets #StockMarket #LivePrices #StockMarketNews #Money #Investing #Investments #Finance #Business #Podcast